Search

Your search keyword '"Hao, Chunyi"' showing total 277 results
Start Over Author "Hao, Chunyi"
277 results on '"Hao, Chunyi"'

3. SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer

Author

Li, Jin, Bai, Yuxian, Chen, Zhendong, Ying, Jieer, Guo, Yabing, Fang, Weijia, Zhang, Feng, Xiong, Jianping, Zhang, Tao, Meng, Zhiqiang, Zhang, Jingdong, Ren, Zhenggang, Hao, Chunyi, Chen, Yajin, Lin, Xiaoyan, Pan, Hongming, Zhou, Fuxiang, Li, Xin, Yu, Fan, Zhang, Juan, Zhang, Zhang, and Qin, Shukui

Published
2024
Full Text
View/download PDF

7. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Author

Strasser, Simone, Thompson, Alexander, Roohullah, Aflah, Sievert, William, Andelkovic, Vladimir, Knox, Jennifer, Davies, Janine, Asselah, Jamil, Brahmania, Mayur, Majeed, Habeeb, Villanueva, Luis, Yanez Weber, Patricio, Garrido, Marcelo, Pizarro, Gonzalo Ignacio, Yanez, Nicolas, Xu, Ruocai, Ou, Shuangyan, Ren, Zhenggang, Pan, Hongming, Meng, Zhiqiang, Gu, Kangsheng, Chen, Xi, Zhang, Tao, Hao, Chunyi, Cao, Peiguo, Guo, Yabing, Qin, Shukui, Xiao, Juxiang, Fang, Weijia, Wang, Xin, Bai, Yuxian, Chen, Xiaoming, Yan, Dong, Zhao, Hong, Ying, Jieer, Bonilla, Carlos, Urrego, Olga, Zambrano, Angela, Lema, Mauricio, Restrepo Gutierrez, Juan Carlos, Cardona, Andres, Franco Millan, Sandra, Oscar, Madiedo, Ramos, Victor, Merle, Philippe, LeSourd, Samuel, Edeline, Julien, Bronowicki, Jean-Pierre, Bourliere, Marc, Cattan, Stephane, Bouattour, Mohamed, Mineur, Laurent, Regnault, Helene, Dauvois, Barbara, Schulze, Kornelius, Folprecht, Gunnar, Geier, Andreas, Waidmann, Oliver, Finkelmeier, Fabian, Venerito, Marino, Berres, Marie-Luise, Berg, Thomas, Lange, Christian, Schmidt, Hartmut, Waldschmidt, Dirk T, Bitzer, Michael, McDermott, Ray, Duffy, Austin, Masi, Gianluca, Zagonel, Vittorina, Tonini, Giuseppe, Piscaglia, Fabio, Gori, Stefania, Rizzo, Mimma, Biscaldi, Elisa, Foltran, Luisa, Cabibbo, Giuseppe, Ikeda, Masafumi, Kudo, Masatoshi, Aikata, Hiroshi, Numata, Kazushi, Marusawa, Hiroyuki, Kato, Naoya, Kurosaki, Masayuki, Morimoto, Manabu, Yamashita, Tatsuya, Koga, Hironori, Masaki, Tsutomu, Tateishi, Ryosuke, Inaba, Yoshitaka, Arakawa, Tomohiro, Suzuki, Yoshiyuki, Akua, Norio, Kobayashi, Masahiro, Hosaka, Tetsuya, Nakamuta, Makoto, Oza, Noriko, Kondo, Shunsuke, Furuse, Junji, Nagashima, Fumio, Kitano, Masayuki, Takaguchi, Koichi, Ryoo, Baek-Yeol, Lim, Ho Yeong, Kim, Jee Hyun, Kim, Tae-You, Kim, Han Sang, Hernandez Hernandez, Carlos, Motola Kuba, Daniel, Segura Gonzalez, Manuel, Cabrera Luviano, Jesus, Huitzil Melendez, Fidel, Ramirez Godinez, Francisco, Silva-Bravo, Fernando, Gane, Edward, Stedman, Catherine, Kwiatkowski, Mariusz, Wyrwicz, Lucjan, Nowakowska-Zajdel, Ewa, Kraj, Leszek, Janczewska, Ewa, Surma-Wlodarczyk, Renata, Breder, Valeriy, Sekacheva, Marina, Orlova, Rashida, Vasilyev, Alexander, Zukov, Ruslan, Vladimirov, Vladimir, Minguez, Beatriz, Matilla Pena, Ana, Fernandez Castroagudin, Javier, Romero Gomez, Manuel, Luis Lledo, Jose, Rubin, Angel, Garcia Sanchez, Araceli, Calleja Panero, Jose, Yu, Ming-Chin, Shen, Ying-Chun, Huang, Yi-Hsiang, Jeng, Long-Bin, Chang, Ting-Tsung, Yang, Sheng-Shun, Chen, Shinn-Cherng, Dechaphunkul, Arunee, Tanwandee, Tawesak, Leerapun, Apinya, Seker, Mesut, Harputluoglu, Hakan, Cicin, Irfan, Oksuzoglu, Berna, Bilici, Mehmet, Sezgin Goksu, Sema, Artac, Mehmet, Cil, Timucin, Yalcin, Suayib, Meyer, Tim, Sarker, Debashis, Rao, Ankit, Palmer, Daniel, Evans, Jeff, Hubner, Richard, Finn, Richard, Ulahannan, Susanna, Zakari, Ahmed, Feun, Lynn, Al-Rajabi, Raed, Sung, Max, He, Aiwu, Kardosh, Adel, Goyal, Lipika, Li, Daneng, Choi, Minsig, Posada, Juan, Dodlapati, Jyothi, Shroff, Rachna, Agrawal, Saurabh, Gopaluni, Srivalli, Akce, Mehmet, Alese, Olatunji, Baron, Ari, Dunne, Richard, Loaiza-Bonilla, Arturo, Frenette, Catherine, Llovet, Josep M, Kumada, Hiromitsu, Cheng, Ann-Lii, Galle, Peter R, Kaneko, Shuichi, Wang, Anran, Mody, Kalgi, Dutcus, Corina, Dubrovsky, Leonid, Siegel, Abby B, and Finn, Richard S

Published
2023
Full Text
View/download PDF

8. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Author

Qin, Shukui, Chan, Stephen L, Cheng, Ann-Lii, Kaseb, Ahmed, Vogel, Arndt, Gu, Shanzhi, Bai, Yuxian, Ren, Zhenggang, Lin, Xiaoyan, Chen, Zhendong, Jia, Weidong, Jin, Yongdong, Guo, Yabing, Hu, Xiaohua, Meng, Zhiqiang, Liang, Jun, Cheng, Ying, Xiong, Jianping, Ren, Hong, Yang, Fang, Li, Wei, Chen, Yajin, Zeng, Yong, Sultanbaev, Alexander, Pazgan-Simon, Monika, Pisetska, Margaryta, Melisi, Davide, Ponomarenko, Dmitriy, Osypchuk, Yurii, Sinielnikov, Ivan, Yang, Tsai-Sheng, Liang, Xiao, Chen, Chunxia, Wang, Linna, Zhang, Mingxiang, Xu, Li, Yuan, Xianglin, Li, Da, Ying, Jierer, Zhang, Jingdong, Zhang, Tao, Gu, Kangsheng, He, Yifu, Hao, Ping, Jiang, Da, Zhang, Shu, Xing, Baocai, Zhang, Baihong, Wang, Dong, Zhai, Xiaofeng, Liang, Houjie, Cybulska-Stopa, Bozena, Dvorkin, Mikhail, Stroyakovskiy, Daniil, Nechaeva, Marina, Yen, Chia-Jui, Su, Wei-Wen, Chen, Yen-Hao, Bondarenko, Igor, Yang, Lin, Fang, Weijia, Gomez-Martin, Carlos, Ryu, Min-Hee, Kim, Han-Sang, Kim, Jee-Hyun, Zarubenkov, Oleg, Orlova, Rashida, Poddubskaya, Elena, Fadeeva, Natalia, Makarova, Yulia, Chao, Yee, Hung, Chao-Hung, Neffa, Maryna, Vynnychenko, Oleksandr, Burgoyne, Adam, Hao, Chunyi, Mohr, Raphael U, Diaz-Beveridge, Roberto, Feliu-Batlle, Jaime, Cubillo-Gracian, Antonio, Lee, Ann-Shing, Daniele, Bruno, Antonuzzo, Lorenzo, Sangiovanni, Angelo, Gasbarrini, Antonio, Scartozzi, Mario, Ahn, Mi Sun, Oh, Sung-Yong, Orlov, Sergey, Harputluoglu, Hakan, Oksuzoglu, Berna, Hsu, Chiun, Rau, Kun-Ming, Krechkovskyi, Oleksandr, Yareshko, Vladimir, Xiong, Henry, Lee, Fa-Chyi, Jiang, Yixing, Gabayan, Afshin, Crow, Mary, Van Steenkiste, Christophe, and Verset, Gontran

Published
2023
Full Text
View/download PDF

9. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Akce, Mehmet, Ales Diaz, Inmaculada, Alves, Gustavo, Anand, Sumitra, Arslan, Cagatay, Asselah, Jamil, Assenat, Eric, Aubin, Francine, Bai, Li-Yuan, Bai, Yuxian, Barajas, Olga, Bates, Susan, Begbie, Stephen, Ben-Aharon, Irit, Beri, Nina, Berres, Marie-Luise, Blanc, Jean-Frederic, Borbath, Ivan, Bordonaro, Robert, Bouattour, Mohamed, Brandi, Giovanni, Burgoyne, Adam, Butthongkomvong, Kritiya, Camandaroba, Marcos, Cao, Ke, Carballido, Marcela, Chan, Stephan Lam, Chen, Jen-Shi, Chen, Ming-Huang, Chen, Xiaoming, Cheng, Ashley, Chiu, Tai-Jan, Choi, Hye Jin, Chon, Hong Jae, Collignon, Joelle, Cubillo Gracian, Antonio, Davis, Sarah, de Carvalho, Ricardo Saraiva, de Groot, D.J.A., Demols, Anne, De Vos, Judith, Diab, Maria, Easaw, Jacob, Eatock, Martin, Edeline, Julien, Elias, Rawad, Eskens, Fredericus, Falcone, Alfredo, Fernandez, Plinio, Finn, Richard, Franke, Fabio, Furukawa, Masayuki, Furuse, Junji, Gbolahan, Olumide, Geboes, Karen, Geneser, Keri-Lee, Geng, Zhimin, Geva, Ravit, Gillmore, Roopinder, Goetze, Thorsten, Gou, Hongfeng, Grasselli, Julieta, Gu, Shanzhi, Gumus, Mahmut, Haj Mohammad, Nadia, Hao, Chunyi, Harputluoglu, Hakan, Hatoum, Hassan, Heinemann, Volker, Ho, Wang Kwong, Hsu, Chiun, Hubert, Ayala, Hwang, Juneul, Inanc, Mevlude, Iseas, Soledad, Jeyasingam, Vaishnavi, Jimenez Fonseca, Paula, Joubert, Warren, Juengsamarn, Jitlada, Kaen, Diego, Kanai, Masashi, Kasper-Virchow, Stefan, Kazemi, Ghazaleh, Kelleher, Fergal, Kelley, Robin, Kim, Jin Won, Kim, Jong Gwang, Kinupe Abrahao, Ana Beatriz, Klumpen, Heinz, Kochenderfer, Mark, Kose, Fatih, Lam, Ho Ching, Lee, Choong-kun, Lee, Hyun Woo, Lee, Margaret, Lee, Myung Ah, Lee, Wai Man Sarah, Le Sourd, Samuel, Li, Dongliang, Li, Wei, Liang, Houjie, Liang, Tingbo, Lim, Chun Sen, Lingerfelt, Brian, Lopez, Charles, Low, John, Macarulla Mercade, Teresa, Malka, David, Mao, Yimin, Masi, Gianluca, McCune, Steven, McDermott, Ray, McWhirter, Elaine, Mendez, Guillermo, Milella, Michele, Mizuno, Nobumasa, Mizutani, Tomonori, Moniz, Camila, Morales, Luisa, Munoz Martin, Andres Jesús, Nervi, Bruno, Ngamphaiboon, Nuttapong, Oh, Sang Cheul, Oksuzoglu, Berna, Outlaw, Darryl, Ozaka, Masato, Ozguroglu, Mustafa, Ozyilkan, Ozgur, Painemal, Claudio, Pan, Yueyin, Park, Joon Oh, Pelzer, Uwe, Peng, Chuang, Petorin, Caroline, Pezet, Denis, Power, Derek, Qin, Shukui, Ren, Zhenggang, Roohullah, Aflah, Ryu, Hyewon, Salman, Pamela, Sasaki, Mitsuhito, Sasidharan, Rita, Satoh, Taroh, Schulze, Kornelius, Scott-Brown, Martin, Segovia, Ruben, Seufferlein, Thomas, Siena, Salvatore, Sinapi, Isabelle, Smolenschi, Cristina, Song, Tianqiang, Sookprasert, Aumkhae, Soparattanapaisarn, Nopadol, Starling, Naureen, Stein, Stacey, Stemmer, Salomon, Su, Haichuan, Sugimoto, Rie, Suksombooncharoen, Thatthan, Tam, Vincent, Tan, Ai Lian, Tan, Chih Kiang, Tanasanvimon, Suebpong, Tonini, Giuseppe, Tortora, Giampaolo, Tsuji, Akihito, Ueno, Makoto, Uribe, Rodrigo, Venerito, Marino, Verdaguer Mata, Helena, Verslype, Chris, Victorino, Ana Paula, Vogel, Arndt, Wade, James, Waldschmidt, Dirk Thomas, Wang, Lu, Wan Isahk, Wan Zamaniah, Wasan, Harpeet, Weschenfelder, Rui, Wong, Chun Yin, Wong, Yoke Fui, Yalcin, Suayib, Yanez Weber, Patricio, Yang, Xuezhong, Yasui, Hisateru, Yau, Thomas, Yazici, Ozan, Yen, Chia-Jui, Ying, Jieer, Yoo, Changhoon, Yu, Wenchang, Zhao, Haitao, Kelley, Robin Kate, Finn, Richard S, Klümpen, Heinz-Josef, Chan, Stephen L, Valle, Juan W, Yu, Li, Malhotra, Usha, and Siegel, Abby B

Published
2023
Full Text
View/download PDF

12. Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer

Author

Cui, Jiujie, Jiao, Feng, Li, Qi, Wang, Zheng, Fu, Deliang, Liang, Jun, Liang, Houjie, Xia, Tingyi, Zhang, Tao, Zhang, Yang, Dai, Guanghai, Zhang, Zhihong, Wang, Jian, Bai, Yongrui, Bai, Yuxian, Bi, Feng, Chen, Donghui, Cao, Dan, Chen, Jie, Fang, Weijia, Gao, Yong, Guo, Jianwei, Hao, Jihui, Hua, Haiqing, Huang, Xinyu, Liu, Wenchao, Liu, Xiufeng, Li, Da, Li, Ji, Li, Enxiao, Li, Zhiwei, Pan, Hongming, Shen, Lin, Sun, Yongwei, Tao, Min, Wang, Chengfeng, Wang, Fenghua, Xiong, Jianping, Zhang, Taiping, Zhang, Xuebin, Zhan, Xianbao, Zheng, Leizhen, Ren, Gang, Zhang, Tingting, Zhou, Jun, Ma, Qingyong, Qin, Shukui, Hao, Chunyi, and Wang, Liwei

Published
2022
Full Text
View/download PDF

14. Advancing treatment efficacy: combined therapy of eribulin, anlotinib, and camrelizumab in advanced or metastatic retroperitoneal liposarcoma.

Author

Jia, Weiwei, Wu, Jianhui, Zhang, Hongtao, Wu, Yan, Liu, Daoning, Wang, Zhen, Wang, Xiaopeng, Li, Chengpeng, and Hao, Chunyi

Abstract

Background: Retroperitoneal liposarcoma (RLPS) typically shows limited response to standard chemotherapy, presenting a challenge in treating advanced or metastatic RLPS. Objective: This study aimed to evaluate the potential advantages of a combined therapeutic strategy utilizing eribulin, anlotinib, and camrelizumab. Design: Between December 2020 and March 2023, this retrospective study enrolled patients with advanced or metastatic RLPS who received treatment at Peking University Cancer Hospital Sarcoma Center. The treatment regimen involved eribulin plus anlotinib and camrelizumab administered every 3 weeks (Q3W). Methods: Efficacy was assessed following the Response Evaluation Criteria in Solid Tumors version 1.1, while safety was evaluated using the Common Terminology Criteria for Adverse Events version 5.0. Results: The study included 47 patients with RLPS with a median age of 55.5 years. Patients received a median of 4.5 (range, 2–21) cycles of treatment. Notably, partial response was observed in 8 patients (18.2%), while 25 (56.8%) exhibited stable disease. The objective response rate (ORR) and disease control rate were 18.2% and 75%, respectively. Significant differences in ORR were observed among histological subtypes (well-differentiated vs de-differentiated vs myxoid: 0 vs 17.9% vs 50%; p = 0.039). Six patients underwent surgery before disease progression, and one patient with myxoid liposarcoma (MLPS) had a pathological complete response. With a median follow-up of 21.8 (range, 2.7–30.7) months, the median progression-free survival (mPFS) was 6.9 (95% confidence interval (CI), 4.7–9.1) months, and the 6-month PFS rate was 60.5%. Based on various histological subtypes, the mPFS was 8.4 (95% CI, 4.1–12.7) months with well-differentiated liposarcoma, 5.8 (95% CI, 3.3–8.3) months with de-differentiated liposarcoma and not reached with MLPS, respectively. Treatment-related adverse events (TRAEs) of any grade occurred in 36 (76.6%) patients, with grade 3 or higher TRAEs in 21 (44.7%) patients. The most common TRAEs were neutropenia (53.2%), proteinuria (21.3%), and anorexia (21.3%). Conclusion: The combined treatment strategy involving eribulin, anlotinib, and camrelizumab showed promising efficacy and manageable safety in patients with advanced or metastatic RLPS, particularly in those with MLPS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Implication of Capillary Morphogenesis Gene 2 (CMG2) in the Disease Progression and Peritoneal Metastasis of Pancreatic Cancer.

Author

Fang, Ziqian, Bunston, Carly, Xu, Yali, Ruge, Fiona, Sui, Laijian, Liu, Ming, Al-Sarireh, Bilal, Griffiths, Paul, Murphy, Kate, Pugh, Matthew R., Hao, Chunyi, Jiang, Wen G., and Ye, Lin

Subjects
MORPHOGENESIS, POLYMERASE chain reaction, HYALURONIC acid, CELLULAR signal transduction, PANCREATIC tumors, METASTASIS, GENE expression, CELL lines, EPIDERMAL growth factor, PROTEOMICS, PERITONEUM tumors, DISEASE progression
Abstract

Simple Summary: Pancreatic cancer remains as one of the most life-threatening cancers with a 5-year overall survival rate less than 6%. As a transmembrane protein, capillary formation gene 2 (CMG2) mediates cell–matrix adhesion and migration. Recent studies have revealed emerging roles of CMG2 in various cancers. This study aimed to evaluate expression of CMG2 in pancreatic cancer and its implication in the disease progression and distant metastasis. Interestingly, the significant upregulation of CMG2 was seen in pancreatic cancer, which was associated with poor survival and distant metastases highlighting the potential of targeting this molecule for the prevention of dissemination of pancreatic cancer cells. Capillary morphogenesis gene 2 (CMG2) mediates cell–matrix interactions to facilitate cell adhesion and migration. CMG2 has been implicated in the disease progression of breast cancer, prostate cancer and gastric cancer. The present study aims to determine the role of CMG2 in the disease progression and peritoneal metastasis of pancreatic cancer. Pancreatic tumour samples were collected from Peking University Cancer Hospital. CMG2 expression was determined using quantitative PCR. After the creation of knockdown and overexpression of CMG2 in pancreatic cancer cells, the effect of CMG2 on several cell functions and adhesion to the peritoneum was examined. Potential pathways regulated by CMG2 were found via proteomics analysis and drug tests. CMG2 was upregulated in pancreatic cancer tissues and associated with a poor prognosis. CMG2 was increased in metastatic lesions and those primary tumours with distant metastases. CMG2 promotes cell–cell, cell–matrix and cell–hyaluronic acid adhesion, which may be mediated by epidermal growth factor receptor (EGFR) and focal adhesion kinase (FAK) pathway activation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Prognostic Nutritional Index (PNI): A More Promising Nutritional Predictor for Patients Undergoing Surgery for Retroperitoneal Liposarcoma.

Author

Xue, Guo-Qiang, Li, Cheng-Peng, Lv, Ang, Wu, Jian-Hui, Tian, Xiu-Yun, Qiu, Hui, and Hao, Chunyi

Subjects
RETROPERITONEUM diseases, RECEIVER operating characteristic curves, NUTRITIONAL assessment, NUTRITIONAL status, CANCER hospitals
Abstract

Background: Extended surgery with multi-visceral resection is the standard treatment for retroperitoneal liposarcoma (RLPS). Malnutrition tends to result in increased surgical complications and reduced survival. The aim of this study was to identify the prognostic role of nutritional status in patients with RLPS. Patients and methods: Data from 189 consecutive patients with RLPS who underwent surgical treatment at the Peking University Cancer Hospital Sarcoma Center between April 2011 and August 2022 were retrospectively reviewed. The following nutritional parameters were calculated: nutritional risk index, prognostic nutritional index (PNI) and Nutrition Risk Screening 2002. Time-dependent receiver operating characteristic (time-ROC) curve analysis was conducted to compare the prognostic utility of nutritional indicators. The associations between nutritional indicators and major complications, local recurrence-free survival (LRFS) and overall survival (OS) were investigated. Results: Based on the time-ROC curve analysis, the PNI was superior to other nutritional indices at predicting OS. The optimal cut-off value of PNI was 41.2. The PNI was significantly inversely associated with tumor size, tumor grade, and histological subtype. Patients in the low PNI group (< 41.2) had significantly shorter LRFS and OS than those in the high PNI (≥ 41.2) group, with higher major morbidity and mortality rates. The PNI was found to be a unique nutritional predictor that independently predicted LRFS and OS in the multivariate analysis. Conclusion: The PNI is an effective tool for nutritional assessment in patients with RLPS. A low PNI value in patients with RLPS predicts worse survival outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial

Author

Chen, Yajin, primary, Du, Cheng-You, additional, Shen, Shunli, additional, Zhang, Wu, additional, Shan, Yunfeng, additional, Lyu, Ang, additional, Wu, Jianhui, additional, Shang, Changzhen, additional, Luo, Xuan, additional, Wei, Jinxing, additional, Xiao, Heng, additional, Qiu, Jianguo, additional, Hua, Yunpeng, additional, Wang, Shutong, additional, Wang, Ting, additional, Dai, Shengjie, additional, Zhang, Shuhao, additional, Xie, Bingying, additional, Wu, Yinghao, additional, and Hao, Chunyi, additional

Published
2024
Full Text
View/download PDF

23. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Author

Llovet, Josep M, primary, Kudo, Masatoshi, additional, Merle, Philippe, additional, Meyer, Tim, additional, Qin, Shukui, additional, Ikeda, Masafumi, additional, Xu, Ruocai, additional, Edeline, Julien, additional, Ryoo, Baek-Yeol, additional, Ren, Zhenggang, additional, Masi, Gianluca, additional, Kwiatkowski, Mariusz, additional, Lim, Ho Yeong, additional, Kim, Jee Hyun, additional, Breder, Valeriy, additional, Kumada, Hiromitsu, additional, Cheng, Ann-Lii, additional, Galle, Peter R, additional, Kaneko, Shuichi, additional, Wang, Anran, additional, Mody, Kalgi, additional, Dutcus, Corina, additional, Dubrovsky, Leonid, additional, Siegel, Abby B, additional, Finn, Richard S, additional, Strasser, Simone, additional, Thompson, Alexander, additional, Roohullah, Aflah, additional, Sievert, William, additional, Andelkovic, Vladimir, additional, Knox, Jennifer, additional, Davies, Janine, additional, Asselah, Jamil, additional, Brahmania, Mayur, additional, Majeed, Habeeb, additional, Villanueva, Luis, additional, Yanez Weber, Patricio, additional, Garrido, Marcelo, additional, Pizarro, Gonzalo Ignacio, additional, Yanez, Nicolas, additional, Ou, Shuangyan, additional, Pan, Hongming, additional, Meng, Zhiqiang, additional, Gu, Kangsheng, additional, Chen, Xi, additional, Zhang, Tao, additional, Hao, Chunyi, additional, Cao, Peiguo, additional, Guo, Yabing, additional, Xiao, Juxiang, additional, Fang, Weijia, additional, Wang, Xin, additional, Bai, Yuxian, additional, Chen, Xiaoming, additional, Yan, Dong, additional, Zhao, Hong, additional, Ying, Jieer, additional, Bonilla, Carlos, additional, Urrego, Olga, additional, Zambrano, Angela, additional, Lema, Mauricio, additional, Restrepo Gutierrez, Juan Carlos, additional, Cardona, Andres, additional, Franco Millan, Sandra, additional, Oscar, Madiedo, additional, Ramos, Victor, additional, LeSourd, Samuel, additional, Bronowicki, Jean-Pierre, additional, Bourliere, Marc, additional, Cattan, Stephane, additional, Bouattour, Mohamed, additional, Mineur, Laurent, additional, Regnault, Helene, additional, Dauvois, Barbara, additional, Schulze, Kornelius, additional, Folprecht, Gunnar, additional, Geier, Andreas, additional, Waidmann, Oliver, additional, Finkelmeier, Fabian, additional, Venerito, Marino, additional, Berres, Marie-Luise, additional, Berg, Thomas, additional, Lange, Christian, additional, Schmidt, Hartmut, additional, Waldschmidt, Dirk T, additional, Bitzer, Michael, additional, McDermott, Ray, additional, Duffy, Austin, additional, Zagonel, Vittorina, additional, Tonini, Giuseppe, additional, Piscaglia, Fabio, additional, Gori, Stefania, additional, Rizzo, Mimma, additional, Biscaldi, Elisa, additional, Foltran, Luisa, additional, Cabibbo, Giuseppe, additional, Aikata, Hiroshi, additional, Numata, Kazushi, additional, Marusawa, Hiroyuki, additional, Kato, Naoya, additional, Kurosaki, Masayuki, additional, Morimoto, Manabu, additional, Yamashita, Tatsuya, additional, Koga, Hironori, additional, Masaki, Tsutomu, additional, Tateishi, Ryosuke, additional, Inaba, Yoshitaka, additional, Arakawa, Tomohiro, additional, Suzuki, Yoshiyuki, additional, Akua, Norio, additional, Kobayashi, Masahiro, additional, Hosaka, Tetsuya, additional, Nakamuta, Makoto, additional, Oza, Noriko, additional, Kondo, Shunsuke, additional, Furuse, Junji, additional, Nagashima, Fumio, additional, Kitano, Masayuki, additional, Takaguchi, Koichi, additional, Kim, Tae-You, additional, Kim, Han Sang, additional, Hernandez Hernandez, Carlos, additional, Motola Kuba, Daniel, additional, Segura Gonzalez, Manuel, additional, Cabrera Luviano, Jesus, additional, Huitzil Melendez, Fidel, additional, Ramirez Godinez, Francisco, additional, Silva-Bravo, Fernando, additional, Gane, Edward, additional, Stedman, Catherine, additional, Wyrwicz, Lucjan, additional, Nowakowska-Zajdel, Ewa, additional, Kraj, Leszek, additional, Janczewska, Ewa, additional, Surma-Wlodarczyk, Renata, additional, Sekacheva, Marina, additional, Orlova, Rashida, additional, Vasilyev, Alexander, additional, Zukov, Ruslan, additional, Vladimirov, Vladimir, additional, Minguez, Beatriz, additional, Matilla Pena, Ana, additional, Fernandez Castroagudin, Javier, additional, Romero Gomez, Manuel, additional, Luis Lledo, Jose, additional, Rubin, Angel, additional, Garcia Sanchez, Araceli, additional, Calleja Panero, Jose, additional, Yu, Ming-Chin, additional, Shen, Ying-Chun, additional, Huang, Yi-Hsiang, additional, Jeng, Long-Bin, additional, Chang, Ting-Tsung, additional, Yang, Sheng-Shun, additional, Chen, Shinn-Cherng, additional, Dechaphunkul, Arunee, additional, Tanwandee, Tawesak, additional, Leerapun, Apinya, additional, Seker, Mesut, additional, Harputluoglu, Hakan, additional, Cicin, Irfan, additional, Oksuzoglu, Berna, additional, Bilici, Mehmet, additional, Sezgin Goksu, Sema, additional, Artac, Mehmet, additional, Cil, Timucin, additional, Yalcin, Suayib, additional, Sarker, Debashis, additional, Rao, Ankit, additional, Palmer, Daniel, additional, Evans, Jeff, additional, Hubner, Richard, additional, Finn, Richard, additional, Ulahannan, Susanna, additional, Zakari, Ahmed, additional, Feun, Lynn, additional, Al-Rajabi, Raed, additional, Sung, Max, additional, He, Aiwu, additional, Kardosh, Adel, additional, Goyal, Lipika, additional, Li, Daneng, additional, Choi, Minsig, additional, Posada, Juan, additional, Dodlapati, Jyothi, additional, Shroff, Rachna, additional, Agrawal, Saurabh, additional, Gopaluni, Srivalli, additional, Akce, Mehmet, additional, Alese, Olatunji, additional, Baron, Ari, additional, Dunne, Richard, additional, Loaiza-Bonilla, Arturo, additional, and Frenette, Catherine, additional

Published
2023
Full Text
View/download PDF

26. Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer

Author

Qin, Shukui, primary, Li, Jin, additional, Bai, Yuxian, additional, Wang, Zishu, additional, Chen, Zhendong, additional, Xu, Ruihua, additional, Xu, Jianming, additional, Zhang, Hongmei, additional, Chen, Jia, additional, Yuan, Ying, additional, Liu, Tianshu, additional, Yang, Lin, additional, Zhong, Haijun, additional, Chen, Donghui, additional, Shen, Lin, additional, Hao, Chunyi, additional, Fu, Deliang, additional, Cheng, Ying, additional, Yang, Jianwei, additional, Wang, Qiong, additional, Qin, Baoli, additional, Pan, Hongming, additional, Zhang, Jun, additional, Bai, Xianhong, additional, and Zheng, Qingshan, additional

Published
2023
Full Text
View/download PDF

27. Consensus of clinical diagnosis and treatment for non-functional pancreatic neuroendocrine neoplasms with diameter <2 cm

Author

Wu, Wenming, primary, Cai, Shouwang, additional, Chen, Rufu, additional, Fu, Deliang, additional, Ge, Chunlin, additional, Hao, Chunyi, additional, Hao, Jihui, additional, Huang, Heguang, additional, Jian, Zhixiang, additional, Jin, Gang, additional, Li, Fei, additional, Li, Haimin, additional, Li, Shengping, additional, Li, Weiqin, additional, Li, Yixiong, additional, Liang, Tingbo, additional, Liu, Xubao, additional, Lou, Wenhui, additional, Miao, Yi, additional, Mou, Yiping, additional, Peng, Chenghong, additional, Qin, Renyi, additional, Shao, Chenghao, additional, Sun, Bei, additional, Tan, Guang, additional, Wang, Huaizhi, additional, Wang, Lei, additional, Wang, Wei, additional, Wang, Weilin, additional, Wei, Junmin, additional, Wu, Heshui, additional, Wu, Zheng, additional, Yan, Changqing, additional, Yang, Yinmo, additional, Yin, Xiaoyu, additional, Yu, Xianjun, additional, Yuan, Chunhui, additional, and Zhao, Yupei, additional

Published
2023
Full Text
View/download PDF

30. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Kelley, Robin Kate, primary, Ueno, Makoto, additional, Yoo, Changhoon, additional, Finn, Richard S, additional, Furuse, Junji, additional, Ren, Zhenggang, additional, Yau, Thomas, additional, Klümpen, Heinz-Josef, additional, Chan, Stephen L, additional, Ozaka, Masato, additional, Verslype, Chris, additional, Bouattour, Mohamed, additional, Park, Joon Oh, additional, Barajas, Olga, additional, Pelzer, Uwe, additional, Valle, Juan W, additional, Yu, Li, additional, Malhotra, Usha, additional, Siegel, Abby B, additional, Edeline, Julien, additional, Vogel, Arndt, additional, Akce, Mehmet, additional, Ales Diaz, Immaculada, additional, Alves, Gustavo, additional, Anand, Sumitra, additional, Arslan, Cagatay, additional, Asselah, Jamil, additional, Assenat, Eric, additional, Aubin, Francine, additional, Bai, Li-Yuan, additional, Bai, Yuxian, additional, Bates, Susan, additional, Begbie, Stephen, additional, Ben-Aharon, Irit, additional, Beri, Nina, additional, Berres, Marie-Luise, additional, Blanc, Jean-Frederic, additional, Borbath, Ivan, additional, Bordonaro, Robert, additional, Brandi, Giovanni, additional, Burgoyne, Adam, additional, Butthongkomvong, Kritiya, additional, Cao, Ke, additional, Carballido, Marcela, additional, Camandaroba, Marcos, additional, Chang, Stephan Lam, additional, Chen, Jen-Shi, additional, Chen, Ming-Huang, additional, Chen, Xiaoming, additional, Cheng, Ashley, additional, Chiu, Tai-Jan, additional, Choi, Hye Jin, additional, Chon, Hong Jae, additional, Collignon, Joelle, additional, Cubillo Gracian, Antonio, additional, Davis, Sarah, additional, de Carvalho, Ricardo Saraiva, additional, de Groot, D.J.A., additional, Demols, Anne, additional, De Vos, Judith, additional, Diab, Maria, additional, Easaw, Jacob, additional, Eatock, Martin, additional, Elias, Rawad, additional, Eskens, Fredericus, additional, Falcone, Alfredo, additional, Fernandez, Plinio, additional, Finn, Richard, additional, Franke, Fabio, additional, Furukawa, Masayuki, additional, Gbolahan, Olumide, additional, Geboes, Karen, additional, Geneser, Keri-Lee, additional, Geng, Zhimin, additional, Geva, Ravit, additional, Gillmore, Roopinder, additional, Goetze, Thorsten, additional, Gou, Hongfeng, additional, Grasselli, Julieta, additional, Gu, Shanzhi, additional, Gumus, Mahmut, additional, Haj Mohammad, Nadia, additional, Hao, Chunyi, additional, Harputluoglu, Hakan, additional, Hatoum, Hassan, additional, Heinemann, Volker, additional, Ho, Wang Kwong, additional, Hsu, Chiun, additional, Hubert, Ayala, additional, Hwang, Juneul, additional, Inanc, Mevlude, additional, Iseas, Soledad, additional, Jeyasingam, Vaishnavi, additional, Jimenez Fonseca, Paula, additional, Joubert, Warren, additional, Juengsamarn, Jitlada, additional, Kaen, Diego, additional, Kanai, Masahi, additional, Kasper-Virchow, Stefan, additional, Kazemi, Ghazaleh, additional, Kelleher, Fergal, additional, Kelley, Robin, additional, Kim, Jin Won, additional, Kim, Jong Gwang, additional, Kinupe Abrahao, Ana Beatriz, additional, Klumpen, Heinz, additional, Kochenderfer, Mark, additional, Kose, Fatih, additional, Lam, Ho Ching, additional, Lee, Choong-kun, additional, Lee, Hyun Woo, additional, Lee, Margaret, additional, Lee, Myung Ah, additional, Lee, Wai Man Sarah, additional, Le Sourd, Samuel, additional, Li, Dongliang, additional, Li, Wei, additional, Liang, Houjie, additional, Liang, Tingbo, additional, Lim, Chun Sen, additional, Lingerfelt, Brian, additional, Lopez, Charles, additional, Low, John, additional, Macarulla Mercade, Teresa, additional, Malka, David, additional, Mao, Yimin, additional, Masi, Gianluca, additional, McCune, Steven, additional, McDermott, Ray, additional, McWhirter, Elaine, additional, Mendez, Guillermo, additional, Milella, Michele, additional, Mizutani, Tomonori, additional, Moniz, Camila, additional, Morales, Luisa, additional, Munoz Martin, Andres Jesús, additional, Nervi, Bruno, additional, Ngamphaiboon, Nuttapong, additional, Oh, Sang Cheul, additional, Oksuzoglu, Berna, additional, Outlaw, Darryl, additional, Ozguroglu, Mustafa, additional, Ozyilkan, Ozgur, additional, Painemeal, Claudio, additional, Pan, Yueyin, additional, Peng, Chuang, additional, Petorin, Caroline, additional, Pezet, Denis, additional, Power, Derek, additional, Qin, Shukui, additional, Roohullah, Aflah, additional, Ryu, Hyewon, additional, Salman, Pamela, additional, Sasidharan, Rita, additional, Satho, Taroh, additional, Schulze, Kornelius, additional, Scott-Brown, Martin, additional, Segovia, Ruben, additional, Seufferlin, Thomas, additional, Siena, Salvatore, additional, Sinapi, Isabelle, additional, Smolenschi, Cristina, additional, Song, Tianqiang, additional, Sookprasert, Aumkhae, additional, Soparattanapaisarn, Nopadol, additional, Starling, Naureen, additional, Stein, Stacey, additional, Stemmer, Salomon, additional, Su, Haichuan, additional, Sugimoto, Rie, additional, Suksombooncharoen, Thatthan, additional, Tam, Vincent, additional, Tan, Ai Lian, additional, Tan, Chih Kiang, additional, Tanasanvimon, Suebpong, additional, Tonini, Giuseppe, additional, Tortora, Giampaolo, additional, Tsuji, Akihito, additional, Uribe, Rodrigo, additional, Venerito, Marino, additional, Verdaguer Mata, Helena, additional, Victorino, Ana Paula, additional, Wade, James, additional, Waldschmidt, Dirk Thomas, additional, Wang, Lu, additional, Wan Isahk, Wan Zamaniah, additional, Wasan, Harpeet, additional, Weschenfelder, Rui, additional, Wong, Chun Yin, additional, Wong, Yoke Fui, additional, Yalcin, Suayib, additional, Yanez Weber, Patricio, additional, Yang, Xuezhong, additional, Yasui, Hisateru, additional, Yazici, Ozan, additional, Yen, Chia-Jui, additional, Ying, Jieer, additional, Yu, Wenchang, additional, and Zhao, Haitao, additional

Published
2023
Full Text
View/download PDF

31. Supplementary Figures 1 - 5, Tables 1 - 3 from CD44-Positive Cancer Stem Cells Expressing Cellular Prion Protein Contribute to Metastatic Capacity in Colorectal Cancer

Author

Du, Lei, primary, Rao, Guanhua, primary, Wang, Hongyi, primary, Li, Baowei, primary, Tian, Weili, primary, Cui, Jiantao, primary, He, Leya, primary, Laffin, Brian, primary, Tian, Xiuyun, primary, Hao, Chunyi, primary, Liu, Hongmin, primary, Sun, Xin, primary, Zhu, Yushan, primary, Tang, Dean G., primary, Mehrpour, Maryam, primary, Lu, Youyong, primary, and Chen, Quan, primary

Published
2023
Full Text
View/download PDF

33. Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

Author

Qin, Shukui, primary, Chen, Zhendong, additional, Fang, Weijia, additional, Ren, Zhenggang, additional, Xu, Ruocai, additional, Ryoo, Baek-Yeol, additional, Meng, Zhiqiang, additional, Bai, Yuxian, additional, Chen, Xiaoming, additional, Liu, Xiufeng, additional, Xiao, Juxiang, additional, Ho, Gwo Fuang, additional, Mao, Yimin, additional, Wang, Xin, additional, Ying, Jieer, additional, Li, Jianfeng, additional, Zhong, Wenyan, additional, Zhou, Yu, additional, Siegel, Abby B., additional, and Hao, Chunyi, additional

Published
2023
Full Text
View/download PDF

35. Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with advanced hepatocellular carcinoma who had failed prior targeted therapy and/or immunotherapy: An open-label, single-arm, phase 1/2 dose-escalation and expansion study.

Author

Ren, Zhenggang, primary, Guo, Yabing, additional, Bai, Yuxian, additional, Ying, Jieer, additional, Meng, Zhiqiang, additional, Chen, Zhendong, additional, Gu, Shanzhi, additional, Zhang, Jingdong, additional, Liang, Jun, additional, Hou, Xinfang, additional, Li, Wei, additional, Xu, Aibing, additional, Hao, Chunyi, additional, Zhang, Jian, additional, Xing, Ruijun, additional, Zhang, Xinyu, additional, Zhang, Dan, additional, and Chan, Stephen Lam, additional

Published
2023
Full Text
View/download PDF

37. Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)

Author

Sun, Hui-Chuan, Zhou, Jian, Wang, Zheng, Liu, Xiufeng, Xie, Qing, Jia, Weidong, Zhao, Ming, Bi, Xinyu, Li, Gong, Bai, Xueli, Ji, Yuan, Xu, Li, Zhu, Xiao-Dong, Bai, Dousheng, Chen, Yajin, Chen, Yongjun, Dai, Chaoliu, Guo, Rongping, Guo, Wenzhi, Hao, Chunyi, Huang, Tao, Huang, Zhiyong, Li, Deyu, Li, Gang, Li, Tao, Li, Xiangcheng, Li, Guangming, Liang, Xiao, Liu, Jingfeng, Liu, Fubao, Lu, Shichun, Lu, Zheng, Lv, Weifu, Mao, Yilei, Shao, Guoliang, Shi, Yinghong, Song, Tianqiang, Tan, Guang, Tang, Yunqiang, Tao, Kaishan, Wan, Chidan, Wang, Guangyi, Wang, Lu, Wang, Shunxiang, Wen, Tianfu, Xing, Baocai, Xiang, Bangde, Yan, Sheng, Yang, Dinghua, Yin, Guowen, Yin, Tao, Yin, Zhenyu, Yu, Zhengping, Zhang, Bixiang, Zhang, Jialin, Zhang, Shuijun, Zhang, Ti, Zhang, Yamin, Zhang, Yubao, Zhang, Aibin, Zhao, Haitao, Zhou, Ledu, Zhang, Wu, Zhu, Zhenyu, Qin, Shukui, Shen, Feng, Cai, Xiujun, Teng, Gaojun, Cai, Jianqiang, Chen, Minshan, Li, Qiang, Liu, Lianxin, Wang, Weilin, Liang, Tingbo, Dong, Jiahong, Chen, Xiaoping, Wang, Xuehao, Zheng, Shusen, and Fan, Jia

Subjects
Review Article, digestive system diseases
Abstract

Recent advances in systemic and locoregional treatments for patients with unresectable or advanced hepatocellular carcinoma (HCC) have resulted in improved response rates. This has provided an opportunity for selected patients with initially unresectable HCC to achieve adequate tumor downstaging to undergo surgical resection, a 'conversion therapy' strategy. However, conversion therapy is a new approach to the treatment of HCC and its practice and treatment protocols are still being developed. Review the evidence for conversion therapy in HCC and develop consensus statements to guide clinical practice. Evidence review: Many research centers in China have accumulated significant experience implementing HCC conversion therapy. Preliminary findings and data have shown that conversion therapy represents an important strategy to maximize the survival of selected patients with intermediate stage to advanced HCC; however, there are still many urgent clinical and scientific challenges for this therapeutic strategy and its related fields. In order to summarize and learn from past experience and review current challenges, the Chinese Expert Consensus on Conversion Therapy for Hepatocellular Carcinoma (2021 Edition) was developed based on a review of preliminary experience and clinical data from Chinese and non-Chinese studies in this field and combined with recommendations for clinical practice. Sixteen consensus statements on the implementation of conversion therapy for HCC were developed. The statements generated in this review are based on a review of clinical evidence and real clinical experience and will help guide future progress in conversion therapy for patients with HCC.

Published
2022

40. Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: A single-arm phase II study.

Author

Hao, Chunyi, primary, Du, Chengyou, additional, Peng, Baogang, additional, Zhang, Wu, additional, Shan, Yunfeng, additional, Lv, Ang, additional, Wu, Jianhui, additional, Shang, Changzhen, additional, Luo, Xuan, additional, Wei, Jinxing, additional, Xiao, Heng, additional, Qiu, Jianguo, additional, Hua, Yunpeng, additional, Shen, Shunli, additional, Wang, Ting, additional, Dai, Shengjie, additional, Chen, Xiang, additional, Yan, Shican, additional, and Hao, Chunyi, additional

Published
2022
Full Text
View/download PDF

41. Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures

Author

Ding, Zhenbin, primary, Wu, Hong, additional, Zeng, Yongyi, additional, Kuang, Ming, additional, Yang, Wei, additional, Meng, Zhiqiang, additional, Chen, Yajin, additional, Hao, Chunyi, additional, Zou, Shubing, additional, Sun, Huichuan, additional, Liu, Chang, additional, Lin, Kecan, additional, Shi, Guoming, additional, Wang, Xiaoying, additional, Fu, Xiutao, additional, Chen, Rongxin, additional, Chen, Yi, additional, Liang, Ruifang, additional, Kano, Takeshi, additional, Pan, Huiyan, additional, Yang, Suna, additional, Fan, Jia, additional, and Zhou, Jian, additional

Published
2022
Full Text
View/download PDF

44. Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.

Author

Qin, Shukui, primary, Bai, Yuxian, additional, Wang, Zishu, additional, Chen, Zhendong, additional, Xu, Ruihua, additional, Xu, Jianming, additional, Zhang, Hongmei, additional, Chen, Jia, additional, Yuan, Ying, additional, Liu, Tianshu, additional, Yang, Lin, additional, Zhong, Haijun, additional, Chen, Donghui, additional, Shen, Lin, additional, Hao, Chunyi, additional, Fu, Deliang, additional, Cheng, Ying, additional, Yang, Jianwei, additional, Bai, Xian hong, additional, and Li, Jin, additional

Published
2022
Full Text
View/download PDF

45. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial

Author

Zheng, Kanglian, primary, Zhu, Xu, additional, Fu, Shijie, additional, Cao, Guang, additional, Li, Wen-Qing, additional, Xu, Liang, additional, Chen, Hui, additional, Wu, Di, additional, Yang, Renjie, additional, Wang, Kun, additional, Liu, Wei, additional, Wang, Hongwei, additional, Bao, Quan, additional, Liu, Ming, additional, Hao, Chunyi, additional, Shen, Lin, additional, Xing, Baocai, additional, and Wang, Xiaodong, additional

Published
2022
Full Text
View/download PDF

46. CD26 as a Promising Biomarker for Predicting Prognosis in Patients with Pancreatic Tumors

Author

Yan, Liang, Tian, Xiuyun, Ye, Chunxiang, Guan, Xiaoya, Dong, Bin, Zhao, Min, Wu, Jianhui, and Hao, Chunyi

Subjects
immunohistochemistry, pancreatic cancer, biomarker, prognosis, OncoTargets and Therapy, Original Research, CD26
Abstract

Liang Yan,1,* Xiuyun Tian,1,* Chunxiang Ye,1,2 Xiaoya Guan,1 Bin Dong,3 Min Zhao,4 Jianhui Wu,1 Chunyi Hao1 1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Hepato-Pancreato-Biliary Surgery, Peking University Cancer Hospital & Institute, Beijing, People’s Republic of China; 2Department of General Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, People’s Republic of China; 3Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Central Laboratory, Peking University Cancer Hospital & Institute, Beijing, People’s Republic of China; 4Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, People’s Republic of China*These authors contributed equally to this workCorrespondence: Chunyi HaoKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Hepato-Pancreato-Biliary Surgery, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing, People’s Republic of ChinaTel +86-10-88196182Fax +86-10-88196548Email haochunyi@bjmu.edu.cnPurpose: Pancreatic cancer is associated with a high mortality rate owing to insufficient approaches for early diagnosis and the invasive biological behavior of the cancer. CD26 is a membrane-anchored protein involved in multiple physiological and pathological processes. Here, we investigated correlations between CD26 expression and clinicopathological features in patients with pancreatic tumors.Methods: We collected 170 tumor tissue specimens and 138 paired paratumoral tissues from patients with pancreatic tumors and evaluated CD26 expression using immunohistochemistry.Results: CD26 was expressed in 79.4% of pancreatic tumors, which was significantly (P < 0.001) higher than that in paratumoral pancreatic tissues (23.2%). High expression of CD26 was correlated with ABO blood type (P = 0.035), malignancy degree (P = 0.001), CA199 (P = 0.01), and CA242 (P = 0.027). In pancreatic malignancies, CD26 expression was observed in 80.7% (130/161) of cases. Lower CD26 expression was correlated with longer disease-free survival (P = 0.048) and overall survival (P = 0.024) and was an independent predictor of overall survival (hazard ratio [HR]: 1.713; P = 0.042). Similar results were observed in pancreatic ductal adenocarcinoma (PDAC) tissues, and CD26 expression level (HR: 2.117; P = 0.008) was an independent predictor of overall survival in patients with PDAC. CD26 expression was significantly increased in pancreatic tumors and gradually increased with increasing malignancy degree, suggesting that CD26 may be involved in the tumorigenic proliferation of pancreatic tumors.Conclusion: Therefore, CD26 is a potential marker for early diagnosis and a promising therapeutic target in pancreatic tumors.Keywords: biomarker, CD26, immunohistochemistry, pancreatic cancer, prognosis

Published
2020

48. Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC).

Author

Zhang, Feng, primary, Bai, Yuxian, additional, Fang, Weijia, additional, Meng, Zhiqiang, additional, Xiong, Jianping, additional, Guo, Yabing, additional, Zhang, Tao, additional, Zhang, Jingdong, additional, Ying, Jieer, additional, Chen, Zhendong, additional, Ren, Zhenggang, additional, Chen, Yajin, additional, Hao, Chunyi, additional, Yang, Liu, additional, Wang, Jun, additional, Zhang, Juan, additional, Yu, Fan, additional, Fei, Cong, additional, Wu, Xikun, additional, and Qin, Shukui, additional

Published
2022
Full Text
View/download PDF

49. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.

Author

Qin, Shukui, primary, Chen, Zhendong, additional, Fang, Weijia, additional, Ren, Zhenggang, additional, Xu, Ruocai, additional, Ryoo, Baek-Yeol, additional, Meng, Zhiqiang, additional, Bai, Yuxian, additional, Chen, Xiaoming, additional, Liu, Xiufeng, additional, Xiao, Juxiang, additional, Ho, Gwo Fuang, additional, Mao, Yimin, additional, Ye, Xing, additional, Ying, Jieer, additional, Li, Jianfeng, additional, Zhong, Wen Yan, additional, Zhou, Yu, additional, Siegel, Abby B., additional, and Hao, Chunyi, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results